CRDF Share Price | Cardiff Oncology, Inc. Stock Analysis & Recommendation

Q: How big is Cardiff Oncology, Inc.?

Market Cap: As of Jun 18, Cardiff Oncology, Inc. has a market capitalization of 246.15 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Cardiff Oncology, Inc. reported net sales of 0.59 million and a net profit of -48.86 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 82.95 million and total assets of 97.19 million.

Q: What does Cardiff Oncology, Inc. do?

Overview: Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing treatment options for cancer patients within the Pharmaceuticals & Biotechnology industry.Financial Snapshot: Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -13 Million (Quarterly Results - Mar 2025) Market cap: USD 246.15 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.12 Return on Equity: -68.93% Price to Book: 3.47Contact Details: Address: 11055 Flintkote Ave, SAN DIEGO CA: 92121-1220 Tel: ['1 858 9527570', '1 858 9527593'] Fax: 1 858 2174768 Website: https://cardiffoncology.com/

Q: Is Cardiff Oncology, Inc. technically bullish or bearish?

As of 15 August 2025, the technical trend for Cardiff Oncology, Inc. has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from the MACD, which is bearish on both weekly and monthly time frames. The daily moving averages also confirm a bearish outlook. Bollinger Bands and KST are mildly bearish on both weekly and monthly periods, while the Dow Theory shows a mixed signal with a mildly bullish weekly stance but a mildly bearish monthly stance. The stock has underperformed significantly against the S&P 500, with a year-to-date return of -50.23% compared to the S&P 500's 12.22%. Overall, the technical indicators suggest a bearish sentiment with considerable weakness.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

428.83 k

Shareholding (Dec 2025)

FII

3.51%

Held by 36 FIIs

DII

76.79%

Held by 16 DIIs

Promoter

7.34%

How big is Cardiff Oncology, Inc.?

22-Jun-2025

As of Jun 18, Cardiff Oncology, Inc. has a market capitalization of 246.15 million, with net sales of 0.59 million and a net profit of -48.86 million over the latest four quarters. The company reported shareholder's funds of 82.95 million and total assets of 97.19 million as of Dec 24.

View full answer

What does Cardiff Oncology, Inc. do?

22-Jun-2025

Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing cancer treatments. As of March 2025, it has a market cap of $246.15 million, with net sales of $0 and a net loss of $13 million.

View full answer

Who are in the management team of Cardiff Oncology, Inc.?

22-Jun-2025

As of March 2022, the management team of Cardiff Oncology, Inc. includes Dr. Rodney Markin (Chairman), Dr. Mark Erlander (CEO), and several independent directors: Dr. Thomas Adams, Dr. James Armitage, Dr. Paul Billings, Mr. John Brancaccio, and Dr. Gary Jacob. This team provides governance and strategic direction for the company.

View full answer

Is Cardiff Oncology, Inc. technically bullish or bearish?

20-Sep-2025

As of August 15, 2025, Cardiff Oncology, Inc. has shifted to a bearish trend, indicated by negative MACD signals and underperformance against the S&P 500, with a year-to-date return of -50.23%.

View full answer

Compare Cardiff Oncology, Inc. with Similar Stocks

VolitionRX Ltd.Cue Health, Inc.Wrap Technologies, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 130 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.23

Return on Equity

-103.34%

Price to Book

2.66

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Dec 2025)

Net Profit:

-7 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-28.0%

6 Months

-16.67%

1 Year

-52.51%

2 Years

-65.18%

3 Years

2.27%

4 Years

-29.96%

5 Years

-82.56%

Cardiff Oncology, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

3.01%

EBIT Growth (5y)

-203.40%

EBIT to Interest (avg)

-38.43

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.12

Sales to Capital Employed (avg)

0.01

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

59.27%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.66

EV to EBIT

-1.30

EV to EBITDA

-1.32

EV to Capital Employed

-6.32

EV to Sales

70.03

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-103.34%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 20 Schemes (12.36%)

Foreign Institutions

Held by 36 Foreign Institutions (3.51%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 38.98% vs -26.88% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.60",
          "val2": "-12.50",
          "chgp": "39.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.20",
          "val2": "-11.80",
          "chgp": "38.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-32,209.90%",
          "val2": "-83,258.30%",
          "chgp": "5,104.84%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -14.29% vs 40.00% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -1.10% vs -9.66% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.60",
          "val2": "0.70",
          "chgp": "-14.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-48.10",
          "val2": "-48.20",
          "chgp": "0.21%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-45.90",
          "val2": "-45.40",
          "chgp": "-1.10%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-82,563.20%",
          "val2": "-71,231.30%",
          "chgp": "-1,133.19%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.20

Operating Profit (PBDIT) excl Other Income

-7.60

-12.50

39.20%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-7.20

-11.80

38.98%

Operating Profit Margin (Excl OI)

-32,209.90%

-83,258.30%

5,104.84%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 38.98% vs -26.88% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.60

0.70

-14.29%

Operating Profit (PBDIT) excl Other Income

-48.10

-48.20

0.21%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-45.90

-45.40

-1.10%

Operating Profit Margin (Excl OI)

-82,563.20%

-71,231.30%

-1,133.19%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is -14.29% vs 40.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -1.10% vs -9.66% in Dec 2024

All Annual Results

Company CV

About Cardiff Oncology, Inc.

Cardiff Oncology, Inc.

Pharmaceuticals & Biotechnology

Cardiff Oncology Inc., formerly Trovagene, Inc., is a clinical-stage biotechnology company. The Company is focused on developing treatment options for cancer patients. It is developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Its clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). Its programs include the development of onvansertib in a Phase-I b/2 study of onvansertib in combination with FOLFIRI/Avastin in mCRC; a Phase II study of onvansertib in combination with Zytiga (abiraterone)/prednisone in Zytiga-resistant mCRPC, and a Phase-II study of onvansertib in combination with decitabine in AML.

Company Coordinates

Company Details

11055 Flintkote Ave , SAN DIEGO CA : 92121-1220

Tel: 1 858 95275701 858 9527593

https://cardiffoncology.com/

Registrar Details